Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Condition(s) studied
Investigational drug(s) / intervention(s)
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg: 1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg: 1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin: 1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
Study summary
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Eligibility
Primary outcome measure(s)
- Time to first occurrence of any of the components of the composite of: •CV death •HF hospitalisation •HF event without hospitalisation — Approximately 36 months
To determine whether balcinrenone/dapagliflozin is superior to dapagliflozin in reducing the risk of CV death and HF events with and without hospitalisation
Trial sites (676)
| Facility | City | Region | Status |
|---|---|---|---|
| Research Site | Alexander City | Alabama | |
| Research Site | Fairhope | Alabama | |
| Research Site | Huntsville | Alabama | |
| Research Site | Phoenix | Arizona | |
| Research Site | Phoenix | Arizona | |
| Research Site | Little Rock | Arkansas | |
| Research Site | Beverly Hills | California | |
| Research Site | Covina | California | |
| Research Site | Encinitas | California | |
| Research Site | Los Angeles | California | |
| Research Site | Los Angeles | California | |
| Research Site | Newport Beach | California | |
| Research Site | Redding | California | |
| Research Site | San Diego | California | |
| Research Site | San Francisco | California | |
| Research Site | San Francisco | California | |
| Research Site | Thousand Oaks | California | |
| Research Site | Vista | California | |
| Research Site | West Hills | California | |
| Research Site | Aurora | Colorado | |
| Research Site | Wheat Ridge | Colorado | |
| Research Site | Altamonte Springs | Florida | |
| Research Site | Boca Raton | Florida | |
| Research Site | Bradenton | Florida | |
| Research Site | Delray Beach | Florida | |
| Research Site | Gainesville | Florida | |
| Research Site | Jacksonville | Florida | |
| Research Site | Miami | Florida | |
| Research Site | Miami | Florida | |
| Research Site | Miami Lakes | Florida | |
| Research Site | Safety Harbor | Florida | |
| Research Site | Saint Augustine | Florida | |
| Research Site | St. Petersburg | Florida | |
| Research Site | Tampa | Florida | |
| Research Site | Atlanta | Georgia | |
| Research Site | Peachtree City | Georgia | |
| Research Site | Tucker | Georgia | |
| Research Site | Chicago | Illinois | |
| Research Site | Hazel Crest | Illinois | |
| Research Site | North Chicago | Illinois |
+ 636 more sites — see the full list on the official registry below.
More AstraZeneca trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06307652 on ClinicalTrials.gov ↗ ← All trials in the USA